TSAO derivatives, inhibitors of HIV-1 reverse transcriptase dimerization: Recent progress

Current Pharmaceutical Design

Volumn 12, Issue 15, 2006, Pages 1895-1907

  Camarasa, M J ^a   Velazquez S ^a   San Felix A ^a   Perez Perez M J ^a   Bonache, M C ^a   De Castro, S ^a  

^a INSTITUTO DE QUÍMICA MÉDICA   (Spain)

Author keywords

Dimerization inhibitors; Nonnucleoside RT inhibitors; Resistance bicyclic nucleosides; Reverse transcriptase (RT); TSAO compounds

Indexed keywords

6 CHLORO 4 (2 CYCLOPROPYLVINYL) 3,4 DIHYDRO 4 TRIFLUOROMETHYL 2(1H) QUINAZOLINONE; [1 [2',5' BIS O (TERT BUTYLDIMETHYLSILYL) BETA DEXTRO RIBOFURANOSYL]THYMINE] 3' SPIRO 5' (4' AMINO 1',2' OXATHIOLE 2',2' DIOXIDE); ABACAVIR; ANTIVIRUS AGENT; CAPRAVIRINE; DAPIVIRINE; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ETRAVIRINE; GW 8248; LAMIVUDINE; N (TERT BUTYLBENZOYL) 2 HYDROXYNAPHTHALDEHYDE HYDRAZONE; NEVIRAPINE; RIBONUCLEASE H; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR DISOPROXIL; TERT BUTYLDIMETHYLSILYLSPIROAMINOOXATHIOLE DIOXIDE; UNCLASSIFIED DRUG; ZALCITABINE; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; CHEMICAL BOND; CLINICAL TRIAL; DIMERIZATION; DRUG BINDING SITE; DRUG EFFICACY; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PRIORITY JOURNAL; REVIEW; STRUCTURE ACTIVITY RELATION; VIRUS REPLICATION; VIRUS RESISTANCE; VIRUS STRAIN;

BINDING SITES; DIMERIZATION; ENZYME STABILITY; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; REVERSE TRANSCRIPTASE INHIBITORS; SPIRO COMPOUNDS; TECHNOLOGY, PHARMACEUTICAL; THYMIDINE;

EID: 33646506098     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161206776873563     Document Type: Review

References (96)

1. UNAIDS/WHO AIDS Epidemic update. December 2004. http://www.unaids.org/ wad2004/report.html.
2. Autran B, Carcelain G, Li TS, Blanc C, Mathez D, Tubiana R, et al. Positive effects of combined antiretroviral therapy on CD4 (+)T cell homeostasis and function in advanced HIV disease. Science 1997; 277: 112-116.
3. Belmonte L, Bare P, De Bracco MM, Ruibal-Ares BH. Reservoirs of HIV Replication After Successful Combined Antiretroviral. Curr Med Chem 2003; 10: 303-312.
4. Saag MS, Kilby JM. HIV-1 and HAART: a time to cure, a time to kill. Nat Med 1997; 5: 609-611.
5. Lee H, Karon JM, Selik R, Neal JJ, Fleming PL. Survival after AIDS diagnosis in adolescents and adults during the treatment era, United States, 1994-1997. JAMA 2001; 285: 1308-1315.
6. Brodt HR, Kamps BS, Gute P, Knupp B, Staszewski S, Helm EB. Changing incidence of AIDS-defining illnesses in the era of antiretroviral combination therapy. AIDS 1997; 11: 1731-1738.
7. Valdez H. Immune restoration after treatment of HIV-1 infection with highly active antiretroviral therapy (HAART). AIDS Rev 2002; 4: 157-164.
8. Kaufmann D, Pantaleo G, Sudre, Telenti A. CD4-cell count in HIV-1-infected individuals remaining viraemic with highly active antiretroviral therapy (HAART). Swiss HIV Cohort Study. Lancet 1998; 351: 723-724.
9. Perrin L, Telenti A. HIV treatment failure: testing for HIV resistance in clinical practice. Science 1998; 280: 1871-1873.
10. Jonckheere H, Anné J, De Clercq E. The HIV-1 reverse transcription (RT) process as target for RT inhibitors. Med Res Rev 2000; 129-154
11. Kohlstaedt LA, Wang J, Fiedman JM, Rice PA, Steitz TA. Crystal structure at 3.5 Å resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science 1992; 256: 1783-1790.
12. Joyce CM, Steitz TA. Polymerase structures and function: variations on a theme? J Bacteriol 1995; 177: 6321-6329.
13. di Marzo V, Copeland TD, De Vico AL, Rahman R, Oroszolan S, Gallo RC, et al. Characterization of highly immunogenic p66/p51 as the reverse transcriptase of HTLV-III/LAV. Science 1986; 231: 1289-1291.
14. Restle T, Müller B, Goody RS. Dimerization of human immunodeficiency virus type 1 reverse transcriptase. A target for chemotherapeutic intervention. J Biol Chem 1990; 265: 8986-8988.
15. Jacobo-Molina A, Ding J, Nanni RG, Clark AD Jr, Lu X, Tantillo C, et al. Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 Å resolution shows bent DNA. Proc Natl Acad Sci USA 1993; 90: 6320-6324.
16. Huang H, Chopra R, Verdine GL, Harrison SC. Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance. Science 1998; 282: 1669-1675.
17. Wang J, Smerdon SJ, Jager J, Kohlstaedt LA, Rice PA, Friedman JM, et al. Structural basis of asymmetry in the human immunodeficiency virus type 1 reverse transcriptase heterodimer. Proc Natl Acad Sci USA 1994; 91: 7242-7246.
18. Harris D, Lee R, Misra HS, Pandey PK, Pandey VN. The p51 subunit of human immunodeficiency virus type 1 reverse transcriptase is essential in loading the p66 subunit on the template primer. Biochemistry 1998; 37: 5903-5908.
19. Müller B, Restle T, Weiss S, Gautel M, Sczakiel G, Goody RS. Co-expression of the subunits of the heterodimer of HIV-1 reverse transcriptase in Escherichia coli. J Biol Chem 1989; 264: 13975-13978.
20. Restle T, Müller B, Goody RS. RNase H activity of HIV reverse transcriptases is confined exclusively to the dimeric forms. FEBS Lett 1992; 300: 97-100.
21. Divita G, Restle T, Goody RS. Characterization of the dimerization process of HIV-1 reverse transcriptase heterodimer using intrinsic protein fluorescence. FEBS Lett 1993; 324: 153-158.
22. Divita G, Rittinger K, Geourjon C, Deláge G, Goody RS. Dimerization kinetics of HIV-1 and HIV-2 reverse transcriptase: a two step process. J Mol Biol 1995; 245: 508-521.
23. De Clercq E. Reverse transcriptase inhibitors as anti-HIV drugs. In: Unger RE, Kreuter J, Rübsamen-Waigmann H Eds, Antivirals against AIDS. Marcel Dekker, Inc., New York, 2000; 107-150.
24. Balzarini J, De Clercq E. (1996) Analysis of inhibition of retroviral reverse transcriptase. Method Enzymol 1996; 275: 472-502
25. Shrama PL, Nurpeisov V, Hernandez-Santiago B, Beltran T, Schinazi RF. Nucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase. Curr Top Med Chem 2004; 4: 895-919.
26. Ren J, Esnouf R, Garman E, Somers D, Ross C, Kirby I, et al. High resolution structures of HIV-1 RT from four RT-inhibitor complexes. Nat Struct Biol 1995; 2: 293-302.
27. Ludovici DW, De Corte BL, Kukla MJ, Ye H, Ho CY, Lichtenstein MA, et al. Evolution of anti-HIV drug candidates. Part 3: Diarylpyrimidine (DAPY) analogues. Bioorg Med Chem Lett 2001; 11: 2235-2239.
28. (a) Ren J, Nichols C, Bird LE, Fujiwara T, Sugimoto H, Stuart DI, et al. Binding of the second generation non-nucleoside inhibitor S-1153 to HIV-1 reverse transcriptase involves extensive main chain hydrogen bonding. J Biol Chem 2000; 275: 14316-14320.
29. (b) De Clercq E. New approaches toward anti-HIV chemotherapy. J Med Chem 2005; 48: 1-17.
30. (a) Pauwels R. New non-nucleoside reverse transcriptase inhibitors (NNRTIs) in development for the treatment of HIV infections. Curr Opin Pharmacol 2004; 4: 437-446.
31. (b) De Corte BL. From 4,5,6,7-tetrahydro-e-methylimidazo[4,5,1-jk](1,4)benzodiazepin-2(1H)-one (TIBO) to etravirine (TMC125): Fifteen years of research on nonnucleoside inhibitors of HIV-1 reverse transcriptase. J Med Chem 2005; 48: 1689-1696.
32. Balzarini J. Current status of the non-nucleoside reverse transcriptase inhibitors of human immunodeficiency virus type 1. Curr Top Med Chem 2004; 4: 921-944.
33. Stammers DK, Somers DO, Ross CK, Kirby I, Ray PH, Wilson JE Crystals of HIV-1 reverse transcriptase diffracting to 2.2 Å resolution. J Mol Biol 1994; 242: 586-588.
34. Hellmig B, Woolf DJ, Debouck C, Harrison SC. The structure of unliganded reverse transcriptase from the human immunodeficiency virus type 1. Proc Natl Acad Sci USA 1995; 92: 1222-1226.
35. Hsiou Y, Ding J, Das K, Clark AD Jr, Boyer PL, Lewi P, et al. The Lys103Asn mutation of HIV-1 RT: a novel mechanism of drug resistance. J Mol Biol 2001; 309: 437-445.
36. Ren J, Nichols C, Bird L, Chamberlain P, Weaver K, Short S, et al. Structural mechanisms of drug resistance for mutations at codons 181 and 188 in HIV-1 reverse transcriptase and the improved resilience of second generation non-nucleoside inhibitors. J Mol Biol 2001; 312: 795-805.
37. Chamberlain PP, Ren J, Nichols CE, Douglas L, Lennerstrand J, Larder BA, et al. Crystal structures of zidovudine- or lamivudine-resistant human immunodeficiency virus type 1 reverse transcriptases containing mutations at codons 41, 184 and 215. J Virol 2002; 76: 10015-10019.
38. Esnouf R, Ren J, Ross C, Jones Y, Stammers D, Stuart D. Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors. Nat Struct Biol 1995; 2: 302-308.
39. Spence RA, Kati WM, Anderson KS, Johnson KA. Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors. Science 1995; 267: 988-993.
40. Peletskaya EN, Kogon M, Tuske S, Arnold E, Hughes SH. Nonnucleoside inhibitor binding affects the interactions of the fingers subdomain of human immunodeficiency virus type 1 reverse transcriptase with DNA. J Virol 2004; 78: 3387-3397.
41. Temiz NA, Bahar I. Inhibitor binding alters the directions of domain motions in HIV-1 reverse transcriptase. Proteins 2002; 49: 61-70.
42. Shen L, Shen J, Luo X, Cheng F, Xu Y, Chen K, et al. Steered molecular dynamics simulation on the binding of NNRTI to HIV-1 RT. Biophys J 2003; 84: 3547-3563.
43. Basavapathruni A, Bailey CM, Anderson KS. Defining a molecular mechanism of synergy between nucleoside and nonnucleoside AIDS drugs. J Biol Chem 2004; 279: 6221-6224.
44. Schinazi RF, Larder BA, Mellors JW. Mutations in retroviral genes associated with drug resistance: 200-2001 update. Int. Antiviral News 2000; 8: 65-91.
45. Vandamme A-M, Van Laethem K, De Clercq E. Managing resistance to anti-HIV drugs. Drugs 1999; 57: 337-361.
46. Schinazi RF, Larder BA, Mellors JW. Mutations in retroviral genes associated with drug resistance. Int Antiviral News 1999; 7: 46-69.
47. (a) Campiani G, Ramunno A, Maga G, Nacci V, Fattorusso C, Catalanotti B, et al. Non-nucleoside HIV-1 reverse transcriptase (RT) inhibitors: past, present, and future perspectives. Curr Pharm Des 2002; 8: 615-657.
48. (b) Das K, Lewi PJ, Hughes SH, Arnold A. Crystallography and the design of anti-AIDS drugs: conformational flexibility and positional adaptability are important in the design of non-nucleoside HIV-1 reverse transcriptase inhibitors. Prog Biophys Mol Biol 2005; 88: 209-231.
49. Balzarini J, Pérez-Pérez MJ, San-Félix A, Schols, D, Perno, CF, Vandamme AM, et al. 2′,5′-Bis-O-(tert- butyldimethylsilyl)-3′-spiro- 5″-(4″-amino-1″,2″- oxathiole-2″,2-dioxide) pyrimidine (TSAO) nucleoside analogues: Highly selective inhibitors of human immunodeficiency virus type 1 that are targeted at the viral reverse transcriptase. Proc Natl Acad Sci USA 1992; 89: 4392-4396.
50. Camarasa MJ, Pérez-Pérez MJ, San-Félix A, Balzarini J, De Clercq E. 3′-Spironucleosides a new class of specific human immunodeficiency virus type 1 inhibitors: Synthesis and antiviral activity of [2′,5′-bis-O-(tert-butyldimethylsilyl)-β- D-xylo and ribofuranose]-3′-spiro-5″-[4″-amino- 1″,2″-oxathiole-2″,2″-dioxide] (TSAO) pyrimidine nucleosides. J Med Chem 1992; 35: 2721-2727.
51. Camarasa MJ, San-Félix A, Velázquez S, Pérez-Pérez M.J, Gago F, Balzarini J. TSAO compounds: The comprehensive story of a unique family of HIV-1 specific inhibitors of Reverse Transcriptase. Curr Top Med Chem 2004; 4: 945-963.
52. Wang J, Smerdon SJ, Jager J, Kohlstaedt LA, Rice PA, Friedman JM, et al. Structural basis of asymmetry in the human immunodeficiency virus type 1 reverse transcriptase heterodimer. Proc Natl Acad Sci USA 1994; 91: 7242-7246.
53. Balzarini J, Karlsson A, Vandamme AM, Pérez-Pérez MJ, Zhang H, Vrang L, et al. Human immunodeficiency virus type 1 (HIV-1) strains selected for resistance against the HIV-1-specific [2′,5′-bis-O-(tert-butyldimethylsilyl)-3′-spiro- 5″-(4″-amino-1″,2″-oxathiole-2″,2″- dioxide)]-β-D-pentofuranosyl (TSAO) nucleoside analogues retain sensitivity to HIV-1-specific nonnucleoside inhibitors. Proc Natl Acad Sci USA 1993; 90: 6952-6956.
54. Jonckheere H, Taymans JM, Balzarini J, Velázquez S, Camarasa MJ, Desmyter J, et al. Resistance of HIV-1 reverse transcriptase against [2′,5′-bis-O-(tert-butyldimethylsilyl)-3′-spiro- 5″-(4″-amino-1″,2″-oxathiole-2″,2″- dioxide)] (TSAO) derivatives is determined by the mutation Glu138-->Lys on the p51 subunit. J Biol Chem 1994; 269: 25255-25258.
55. Boyer PL, Ding J, Arnold E, Hughes SH. Subunit specificity of mutations that confer resistance to nonnucleoside inhibitors in human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother 1994; 38: 1909-1914.
56. (a) Balzarini J, Pérez-Pérez MJ, San-Félix A, Camarasa MJ, Barr PJ, De Clercq E. Interaction of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase with the novel HIV-1 specific nucleoside analogue 1-[2′,5′-bis-O-(tert-butyldimethylsilyl)- b-Dribofuranosyl]-3′-spiro-5″-[4″-amino-1″, 2″-oxathiole-2″,2″-dioxide] thymine (TSAO-T). Arch Int Phys Biochem Biophys 1992; 100: B28.
57. (b) Camarasa MJ, Pérez-Pérez MJ, Velázquez S, San-Félix A, Alvarez R, Ingate S, et al. TSAO derivatives: Highly specific inhibitors of human immunodeficiency virus type-1 (HIV-1) replication. Nucleosides Nucleotides 1995; 14: 585-594.
58. (c) Balzarini J, Camarasa MJ, Karlsson A. TSAO derivatives: Highly specific human immunodeficiency virus type 1 (HIV-1) reverse transcriptase inhibitors. Drugs Future 1993; 18: 1043-1055.
59. Balzarini J, Pérez-Pérez MJ, San-Félix A, Camarasa MJ, Bathurst IC, Barr PJ, et al. Kinetics of inhibition of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase by the novel HIV-1 specific nucleoside analogue 2′,5′-bis-O-(t- butyldimethylsilyl)-3′-spiro- 5″-(4″-amino-1″,2″- oxathiole-2″,2″-dioxide) thymine (TSAO-T). J Biol Chem 1992; 267: 11831-11838.
60. Rodríguez-Barrios F, Pérez C, Lobatón E, Velázquez S, Chamorro C, San-Félix A, et al . Identification of a putative binding site for [2′,5′-Bis-O- (tert-butyldimethylsilyl)-β-D-ribofuranosyl]-3′-spiro-5″- (4″-amino-1″,2″-oxathiole-2″,2″- dioxide)thymine (TSAO) derivatives at the p51-p66 interface of HIV-1 reverse transcriptase. J Med Chem 2001; 44: 1853-1865.
61. Harris D, Lee R, Misra HS, Pandey PK, Pandey VN. The p51 subunit of human immunodeficiency virus type 1 reverse transcriptase is essential in loading the p66 subunit on the template primer. Biochemistry 1998; 37: 5903-5908.
62. Sluis-Cremer N, Dmitrienko GI, Balzarini J, Camarasa MJ, Parniak MA. Human immunodeficiency virus type 1 reverse transcriptase dimer destabilization by 1-[Spiro[4″-amino-2″,2″-dioxo- 1″,2″-oxathiole-5″,3′-[2′,5′-bis-O- (tert-butyldimethylsilyl)-β-D-ribofuranosyl]]]3-ethylthymine. Biochemistry 2000; 39: 1427-1433.
63. Alvarez R, Jimeno ML, Gago F, Balzarini J, Perez-Perez MJ, Camarasa MJ. Novel 3′-spiro nucleoside analogues of TSAO-T. Part II. A comparative study based on NMR conformational analysis in solution and theoretical calculations. Antivir Chem Chemother 1998; 9: 333-340.
64. Becerra SP, Kumar A, Lewis MS, Widen SG, Abbotts J, Karawya EM, et al. Protein-protein interactions of HIV-1 reverse transcriptase: implications of central and C-terminal regions in subunit binding. Biochemistry 1991; 30: 11707-1719.
65. Samanta U, Chakrabarti P. Assessing the role of tryptophan residues in the binding site. Protein Eng 2001; 14: 7-15.
66. Tachedjian G, Aronson HEG, de los Santos M, Seehra J, McCoy JM, Goff SP. Role of residues in the tryptophan repeat motif for HIV-1 reverse transcriptase dimerization. J Mol Biol 2003; 326, 381-396.
67. Baillon JG, Nashed NT, Kumar A, Wilson SH, Jerina DM. A leucine zipper-like motif may mediate HIV reverse transcriptase subunit binding. New Biol 1991; 3: 1015-1019.
68. Goel R, Beard WA, Kumar A, Casas-Finet JR, Strub MP, Stahl SJ, et al. Structure/function studies of HIV-1 reverse transcriptase: dimerization-defective mutant L289K. Biochemistry 1993; 32: 13012-13018.
69. Divita G, Restle T, Goody RS, Chermann JC, Baillon JG. Inhibition of human immunodeficiency virus type 1 reverse transcriptase dimerization using synthetic peptides derived from the connection domain. J Biol Chem 1994; 269: 13080-13083.
70. Divita G, Rittinger K, Geourjon C, Deléage G, Goody RS. (1995) Dimerization kinetics of HIV-1 and HIV-2 reverse transcriptase: a two step process. J Mol Biol 1995; 245: 508-521.
71. Morris MC, Robert-Hebmann V, Chaloin VL, Mery J, Heitz F, Devaux C, et al. A new potent HIV-1 reverse transcriptase inhibitor. J Biol Chem 1999; 274: 24941-24946.
72. Depollier J, Hourdou ML, Aldrian-Herrada G, Rothwell P, Restle T, Divita G. Insight into the mechanism of a peptide inhibitor of HIV reverse transcriptase dimerization. Biochemistry 2005; 44: 1909-1918.
73. Pandey PK, Kaushik N, Talele TT, Yadav PNS, Pandey VN. The β7-β8 loop of the p51 subunit in the heterodimeric (p66/p51) human immunodeficiency virus type 1 reverse transcriptase is essential for the catalytic function of the p66 subunit. Biochemistry 2001; 40: 9505-9512.
74. Pandey PK, Kaushik N, Singh K, Sharma B, Upadhyay AK, Kumar S, et al. Insertion of a small peptide of six amino acids into the β7-β8 loop of the p51 subunit of HIV-1 reverse transcriptase perturbs the heterodimer and affects its activities. BMC Biochem 2002; 3: 18-31.
75. Sluis-Cremer N, Arion D, Parniak MA. Destabilization of the HIV-1 reverse transcriptase dimer upon interaction with N-acyl hydrazone inhibitors. Mol Pharmacol 2002; 62: 398-405.
76. Sluis-Cremer N, Tachedjian G. Modulation of the oligomeric structures of HIV-1 retroviral enzymes by synthetic peptides and small molecules. Eur J Biochem 2002; 269: 5103-5111.
77. Tachedjian G, Goff SP. The effect of NNRTIs on HIV reverse transcriptase dimerization. Curr Opin Investig Drugs 2003; 4: 966-973.
78. Tachedjian G, Orlova M, Sarafianos SG, Arnold E, Goff SP. Nonnucleoside reverse transcriptase inhibitors are chemical enhancers of dimerization of the HIV type 1 reverse transcriptase. Proc Natl Acad Sci USA 2001; 98: 7188-7193.
79. Tachedjian G, Moore KL, Goff SP, Sluis-Cremer N. Efavirenz enhances the proteolytic processing of an HIV-1 pol polyprotein precursor and reverse transcriptase homodimer formation. FEBS Lett 2005; 579: 379-384.
80. Sluis-Cremer N, Temiz NA, Bahar I. Conformational changes in HIV-1 reverse transcriptase induced by nonnucleoside reverse transcriptase inhibitor binding. Curr HIV Res 2004; 2: 323-332.
81. Arion D, Sluis-Cremer N, Min KL, Abram ME, Fletcher RS, Parniak MA. Mutational analysis of Tyr-501 of HIV-1 reverse transcriptase. Effects on ribonuclease H activity and inhibition of this activity by N-acylhydrazones. J Biol Chem 2002; 277: 1370-1374.
82. Borkow G, Fletcher RS, Barnard J, Arion D, Motakis D, Dmitrienko GI, et al. Inhibition of the ribonuclease H and DNA polymerase activities of HIV-1 reverse transcriptase by N-(4-tertbutylbenzoyl)-2-hydroxy-1-naphthaldehyde hydrazone. Biochemistry 1997; 36: 3179-3185.
83. Lobatón E, Rodríguez-Barrios F, Gago F, Pérez-Pérez MJ, De Clercq E, Balzarini J, et al. Synthesis of 3″-substituted TSAO derivatives with anti-HIV-1 and anti-HIV-2 activity through an efficient palladium-catalyzed cross-coupling approach. J Med Chem 2002; 45: 3934-3945.
84. Lobatón E, Camarasa MJ, Velázquez S. An efficient synthesis of 3′-spiro sultone nucleosides functionalized on the sultone moiety via Pd-catalyzed cross-coupling reaction. Synlett 2000; 9: 1312-1314.
85. De Castro S, Lobatón E, Pérez-Pérez MJ, San-Félix A, Cordeiro A, Andrei A, et al. Novel [2′,5′-bis-O-(tert-butyldimethylsilyl)-β- D-ribofuranosyl]-3′-spiro-5″-(4″-amino-1″, 2″-oxathiole-2″,2″-dioxide) derivatives with anti-HIV-1 and anti-human-cytomegalovirus activity. J Med Chem 2005; 48: 1158-1168.
86. (a) Bonache MC, Chamorro C, Velázquez S, De Clercq E, Balzarini J, Camarasa MJ, et al. N-3 substituted TSAO derivatives as a probe to explore the dimeric interface of HIV-1 reverse transcriptase. Nucleosides Nucleotides Nucleic Acids 2003; 22: 947-949.
87. (b) Bonache MC, Chamorro C, Velázquez S, De Clercq E, Balzarini J, Rodríguez-Barrios F, et al. Novel N-3-substituted TSAO-T aimed at enhancing the interaction with the dimer interface of HIV-1 reverse transcriptase. J Med Chem 2005; Submitted.
88. Chamorro C, Lobatón E, Bonache MC, De Clercq E, Balzarini J, Velázquez S, et al. Identification of a novel family of nucleosides that specifically inhibit HIV-1 reverse transcriptase. Bioorg Med Chem Lett 2001; 11: 3085-3088.
89. Bonache MC, Chamorro C, Lobatón E, De Clercq E, Balzarini J, Velázquez S, et al. Structure-activity relationship studies on a novel family of specific HIV-1 reverse transcriptase inhibitors. Antivir Chem Chemother 2003; 14: 249-262.
90. Camorro C, Luengo SM, Bonache MC, Velázquez S, Pérez-pérez MJ, Camarasa MJ, et al . Synthesis and structural characterization of pyrimidine bi- and tricyclic nucleosides with sugar puckers conformationally locked into the eastern region of the pseudorotational cycle. J Org Chem 2003; 68: 6695-6704.
91. Bonache MC, Chamorro C, Cordeiro A, Camarasa MJ, Jimeno ML, San-Félix A. Synthesis of novel bi-, tri-, and tetracyclic nucleosides by reaction of a common cyclic enamine derived from TSAO-T with nucleophiles. J Org Chem 2004; 69: 8758-8766.
92. Cordeiro A, Bonache MC, De Clercq E, Balzarini J, Camarasa MJ, San-Félix A. Unusual tricyclic nucleosides derived from TSAO with activity against immunodeficiency virus type 1. Abstract 209.78001. 18th International Conference on Antiviral Research: 2005 April 10-14; Barcelona (Spain).
93. Balzarini J, Naesens L, Bohman C, Pérez-Pérez MJ, San-Félix A, Camarasa MJ, et al. Metabolism and pharmacokinetics of the anti-HIV-1-specific inhibitor [1-[2′,5′-bis-O-(tert- butyldimethylsilyl)-β- D-ribofuranosyl]- 3-N-methyl-thymine]-3′- spiro-5″-(4″-amino-1″,2″- oxathiole-2″,2″-dioxide). Biochem Pharmacol 1993; 46: 69-77.
94. Burlet S, Pietrancosta N, Laras Y, Garino C, Quelever G, Kraus JL. Prospects for the resistance to HIV protease inhibitors: current drug design approaches and perspectives. Curr Pharm Des 2005; 11(24): 3077-90.
95. Pereira CF, Paridaen JT. Anti-HIV drug development - an overview. Curr Pharm Des 2004; 10(32): 4005-37.
96. Thomas SA. Anti-HIV drug distribution to the central nervous system. Curr Pharm Des 2004; 10(12): 1313-24.